Search

Your search keyword '"Xu, Aimin"' showing total 1,998 results
Start Over Author "Xu, Aimin"
1,998 results on '"Xu, Aimin"'

3. Aging Degree Detection of Insulator Umbrella Skirt Based on Laser-Induced Breakdown Spectroscopy

Author

Song, Ziyuan, Gao, Yibo, Guo, Xinyu, Xu, Aimin, Li, Jinghui, Shi, Mingxin, Hu, Yujia, Wu, Jian, Angrisani, Leopoldo, Series Editor, Arteaga, Marco, Series Editor, Chakraborty, Samarjit, Series Editor, Chen, Jiming, Series Editor, Chen, Shanben, Series Editor, Chen, Tan Kay, Series Editor, Dillmann, Rüdiger, Series Editor, Duan, Haibin, Series Editor, Ferrari, Gianluigi, Series Editor, Ferre, Manuel, Series Editor, Jabbari, Faryar, Series Editor, Jia, Limin, Series Editor, Kacprzyk, Janusz, Series Editor, Khamis, Alaa, Series Editor, Kroeger, Torsten, Series Editor, Li, Yong, Series Editor, Liang, Qilian, Series Editor, Martín, Ferran, Series Editor, Ming, Tan Cher, Series Editor, Minker, Wolfgang, Series Editor, Misra, Pradeep, Series Editor, Mukhopadhyay, Subhas, Series Editor, Ning, Cun-Zheng, Series Editor, Nishida, Toyoaki, Series Editor, Oneto, Luca, Series Editor, Panigrahi, Bijaya Ketan, Series Editor, Pascucci, Federica, Series Editor, Qin, Yong, Series Editor, Seng, Gan Woon, Series Editor, Speidel, Joachim, Series Editor, Veiga, Germano, Series Editor, Wu, Haitao, Series Editor, Zamboni, Walter, Series Editor, Tan, Kay Chen, Series Editor, Yang, Qingxin, editor, Li, Zewen, editor, and Luo, An, editor

Published
2024
Full Text
View/download PDF

7. Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota

Author

Li, Huating, Zhang, Lei, Li, Jun, Wu, Qian, Qian, Lingling, He, Junsheng, Ni, Yueqiong, Kovatcheva-Datchary, Petia, Yuan, Rui, Liu, Shuangbo, Shen, Li, Zhang, Mingliang, Sheng, Bin, Li, Ping, Kang, Kang, Wu, Liang, Fang, Qichen, Long, Xiaoxue, Wang, Xiaolin, Li, Yanli, Ye, Yaorui, Ye, Jianping, Bao, Yuqian, Zhao, Yueliang, Xu, Guowang, Liu, Xinyu, Panagiotou, Gianni, Xu, Aimin, and Jia, Weiping

Published
2024
Full Text
View/download PDF

8. Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease

Author

Chui Zara Siu Wa, Xue Yaqian, and Xu Aimin

Subjects
metabolic hormones, metabolic dysfunction-associated steatohepatitis (mash), liver fibrosis, biopharmaceutical development, clinical trials, Medicine
Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached epidemic proportions globally in parallel to the rising prevalence of obesity. Despite its significant burden, there is no approved pharmacotherapy specifically tailored for this disease. Many potential drug candidates for MAFLD have encountered setbacks in clinical trials, due to safety concerns or/and insufficient therapeutic efficacy. Nonetheless, several investigational drugs that mimic the actions of endogenous metabolic hormones, including thyroid hormone receptor β (THRβ) agonists, fibroblast growth factor 21 (FGF21) analogues, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), showed promising therapeutic efficacy and excellent safety profiles. Among them, resmetirom, a liver-targeted THRβ-selective agonist, has met the primary outcomes in alleviation of metabolic dysfunction-associated steatohepatitis (MASH), the advanced form of MAFLD, and liver fibrosis in phase-3 clinical trials. These hormone-based pharmacotherapies not only exhibit varied degrees of therapeutic efficacy in mitigating hepatic steatosis, inflammation and fibrosis, but also improve metabolic profiles. Furthermore, these three hormonal agonists/analogues act in a complementary manner to exert their pharmacological effects, suggesting their combined therapies may yield synergistic therapeutic benefits. Further in-depth studies on the intricate interplay among these metabolic hormones are imperative for the development of more efficacious combination therapies, enabling precision management of MAFLD and its associated comorbidities.

Published
2024
Full Text
View/download PDF

16. Risk assessment with gut microbiome and metabolite markers in NAFLD development

Author

Leung, Howell, Long, Xiaoxue, Ni, Yueqiong, Qian, Lingling, Nychas, Emmanouil, Siliceo, Sara Leal, Pohl, Dennis, Hanhineva, Kati, Liu, Yan, Xu, Aimin, Nielsen, Henrik B, Belda, Eugeni, Clément, Karine, Loomba, Rohit, Li, Huating, Jia, Weiping, and Panagiotou, Gianni

Subjects
Chronic Liver Disease and Cirrhosis, Hepatitis, Prevention, Nutrition, Liver Disease, Clinical Research, Digestive Diseases, Aetiology, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 2.1 Biological and endogenous factors, Oral and gastrointestinal, Biomarkers, Gastrointestinal Microbiome, Humans, Non-alcoholic Fatty Liver Disease, Prospective Studies, Risk Assessment, Biological Sciences, Medical and Health Sciences
Abstract

A growing body of evidence suggests interplay between the gut microbiota and the pathogenesis of nonalcoholic fatty liver disease (NAFLD). However, the role of the gut microbiome in early detection of NAFLD is unclear. Prospective studies are necessary for identifying reliable, microbiome markers for early NAFLD. We evaluated 2487 individuals in a community-based cohort who were followed up 4.6 years after initial clinical examination and biospecimen sampling. Metagenomic and metabolomic characterizations using stool and serum samples taken at baseline were performed for 90 participants who progressed to NAFLD and 90 controls who remained NAFLD free at the follow-up visit. Cases and controls were matched for gender, age, body mass index (BMI) at baseline and follow-up, and 4-year BMI change. Machine learning models integrating baseline microbial signatures (14 features) correctly classified participants (auROCs of 0.72 to 0.80) based on their NAFLD status and liver fat accumulation at the 4-year follow up, outperforming other prognostic clinical models (auROCs of 0.58 to 0.60). We confirmed the biological relevance of the microbiome features by testing their diagnostic ability in four external NAFLD case-control cohorts examined by biopsy or magnetic resonance spectroscopy, from Asia, Europe, and the United States. Our findings raise the possibility of using gut microbiota for early clinical warning of NAFLD development.

Published
2022

32. Low-Level Environmental Per- and Polyfluoroalkyl Substances and Preterm Birth: A Nested Case–Control Study Among a Uyghur Population in Northwestern China

Author

Yang, Bo-Yi, Wu, Jianhua, Niu, Xilong, He, Chuanjiang, Bloom, Michael S., Abudoukade, Maihefuzaimu, Abulizi, Mairiyemu, Xu, Aimin, Li, Beibei, Li, Li, Zhong, Xuemei, Wu, Qi-Zhen, Chu, Chu, Luo, Ya-Na, Liu, Xiao-Xuan, Zeng, Xiao-Wen, Yu, Yunjiang, Dong, Guang-Hui, Zou, Xiaoguang, and Liu, Tao

Published
2022
Full Text
View/download PDF

35. An efficient numerical method for a time-fractional diffusion equation

Author

Cen, Zhongdi, Huang, Jian, Le, Anbo, and Xu, Aimin

Subjects
Mathematics - Numerical Analysis
Abstract

A reaction-diffusion problem with a Caputo time derivative is considered. An integral discretization scheme on a graded mesh along with a decomposition of the exact solution is proposed. The truncation error estimate of the discretization scheme is derived by using the remainder formula of the linear interpolation and some inequality estimate techniques. It is proved that the scheme is second-order convergent by applying a difference analogue of Gronwall's inequality, which exhibits an enhancement in the convergence rate compared with the L1 schemes. Numerical experiments are presented to support the theoretical result.

Published
2018

44. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)

Author

Ong, Kwok Leung, Hui, Nicholas, Januszewski, Andrzej S, Kaakoush, Nadeem O, Xu, Aimin, Fayyad, Rana, DeMicco, David A, Jenkins, Alicia J, Keech, Anthony C, Waters, David D, Barter, Philip J, and Rye, Kerry-Anne

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Heart Disease, Clinical Trials and Supportive Activities, Cardiovascular, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Anticholesteremic Agents, Atorvastatin, Biomarkers, Cardiovascular Diseases, Coronary Artery Disease, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Predictive Value of Tests, Endocrinology & Metabolism, Clinical sciences
Abstract

BackgroundHigher plasma fibroblast growth factor 21 (FGF21) levels predict incident cardiovascular events in type 2 diabetes patients. However, whether FGF21 levels predict cardiovascular events in statin-treated patients in the general population is unknown. We investigated whether FGF21 levels predict major cardiovascular event (MCVE) in the Treating to New Targets (TNT) trial participants.MethodsAfter 8-week run-in on atorvastatin 10 mg/day, 10,001 patients with stable coronary disease in the TNT trial were randomized to 10 mg or 80 mg/day of atorvastatin for a median of 4.9 years. We analyzed data from 1996 patients with plasma FGF21 levels measured at randomization. Among them, 1835 patients had FGF21 measured one-year post-randomization.ResultsHigher ln-transformed FGF21 levels at randomization were associated with higher risk of incident MCVE (adjusted hazards ratio per SD increase = 1.18, P = 0.019). At 1-year post-randomization, FGF21 levels were lower in patients randomized to receive 80 mg versus 10 mg atorvastatin (186.9 versus 207.5 pg/mL respectively, P = 0.006). Higher ln-transformed FGF21 levels at 1-year post-randomization were also associated with higher subsequent risk of MCVEs (adjusted hazards ratio per SD increase = 1.24, P = 0.009). However, changes in FGF21 levels over 1-year were not related to subsequent MCVE risk. FGF21 levels had significant incremental value in net reclassification improvement in MCVE risk prediction.ConclusionsHigher plasma FGF21 levels are associated with higher CVD risk in statin-treated high-risk patients. Higher dose atorvastatin is associated with a reduction in FGF21 levels. FGF21 provides incremental value in CVD risk prediction in statin-treated patients.

Published
2019

46. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model

Author

Lian, Qizhou, Zhang, Kui, Zhang, Zhao, Duan, Fuyu, Guo, Liyan, Luo, Weiren, Mok, Bobo Wing-Yee, Thakur, Abhimanyu, Ke, Xiaoshan, Motallebnejad, Pedram, Nicolaescu, Vlad, Chen, Jonathan, Ma, Chui Yan, Zhou, Xiaoya, Han, Shuo, Han, Teng, Zhang, Wei, Tan, Adrian Y., Zhang, Tuo, Wang, Xing, Xu, Dong, Xiang, Jenny, Xu, Aimin, Liao, Can, Huang, Fang-Ping, Chen, Ya-Wen, Na, Jie, Randall, Glenn, Tse, Hung-fat, Chen, Zhiwei, Chen, Yin, and Chen, Huanhuan Joyce

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results